tbuckley/cabot-search huggingface dataset:
Female germ cell tumors (GCT): The Memorial Sloan Kettering Cancer Center (MSKCC) experience.
Authors: Jane Lowe Meisel, Kaitlin Woo, Nora Sudarsan, Jana Eng, Sujata Patil, Erin Patricia Jacobsen, Rajmohan Murali, Robert J. Motzer, George J. Bosl, Carol Aghajanian, Darren Richard Feldman
Journal: Journal of Clinical Oncology (2014)

5539 Background: Due to their rarity, little is known about female GCT biology and response to therapy. Management is largely based on studies of male GCT and epithelial ovarian cancer. Methods: We identified 111 female patients (pts) treated at MSKCC for malignant GCT of gynecologic origin from 1990 to 2012 and reviewed their clinical characteristics and outcomes. Pts receiving chemotherapy (CT) were classified using a modification of the IGCCCG system for men. Kaplan-Meier methods were used to estimate progression-free (PFS) and overall survival (OS) and the log-rank test to assess differences. Results: Histologies in the 111 pts (107 ovarian) included immature teratoma (28), dysgerminoma (DG) (24), mixed GCT (20), yolk sac (18), mature cystic teratoma (MCT) (12), struma ovarii (SO) (6), and other (3). 72 (65%) were stage I, 5 (5%) stage II, 28 (25%) stage III, and 6 (5%) stage IV. All pts underwent primary surgery and 85 (77%) received CT; in 67 (79%), BEP was the 1st-line regimen. IGCCCG risk was good in 46 (54%), intermediate in 12 (14%), poor in 10 (12%) and unknown in 17 (serum tumor markers (STM) not drawn at CT start). AFP, HCG, and LDH were elevated in 36, 6, and 11 pts, respectively. Complete response (CR) to 1st-line CT was seen in 64 (75%), partial response in 1, and incomplete response (IR) in 20 (24%). 29 (26%) pts progressed after initial therapy (26 after CT), with 14/29 (52%) diagnosed by imaging, 6 by STM, 1 by exam, and 8 by multiple methods. 11/26 (42%) who progressed after CT received high-dose CT (HDCT) with ASCT resulting in 6 CRs and 5 IRs. 4/6 CRs had received only 1 prior CT regimen vs 2/5 IR pts. With median f/u of 4.9 years (y), 3yOS for all pts was 86% (95% CI 79-93%), with a trend favoring DG, SO, and MCT vs other histologies (97% vs 83%, p=0.056) and Stage I/II vs III/IV (88% vs 81%, p=0.067). IGCCCG group was significantly associated with PFS and OS (Table). Conclusions: IGCCCG status can help estimate prognosis to CT for female GCT pts. Thus, STM should always be drawn prior to CT, and poor-risk pts might benefit from more intensive 1st-line CT. Salvage HDCT, especially if given early, can be curative. PFS and OS to CT by IGCCCG Group. Good (n=45)* Intermediate (n=12) Poor (n=10) Log-rank P 3y-PFS 84% 83% 20% <0.001 3y-OS 89% 89% 40% <0.001 * n = 44 for OS.
Economic analysis of pharmacokinetic (PK) studies in phase I clinical trials.
Authors: Badi Edmond El Osta, Gerald Steven Falchook, Diane Schaub, Harihara Subramanian, Maryam Daneshmand, Dina Harleaux, Daniel D. Karp
Journal: Journal of Clinical Oncology (2013)

3103 Background: Although PK evaluation is a prevalent and critical component of cancer drug development, optimization of the cost-value relationship of PK studies has not been evaluated. Methods: We reviewed 26 phase I protocols that were activated and performed in the Clinical &amp; Translational Research Center at U.T. MD Anderson Cancer Center from 2010 to 2012. 23 protocols met the residual analysis criteria of a normal and independent distribution. We collected protocol-specific data including medication, route, frequency, mechanism of action, number of enrolled patients, number of PK time points, and PK charges. Results: All 23 protocols were funded by industry sponsors. During 2010-2012: the total number of patients was 560; the median number of patients enrolled per protocol at our site was 18 (range 3-84); the median number of total PK studies per patient performed on each protocol was 19.46 (4.11-36.92); the median charge of PK time points was $42.33 (35.02-80.00); the median charge of all PK time points per patient on a protocol was $813.00 (329.00-1676.00); the median number of total PK studies per patient on a protocol during cycle 1 was 15.20 (2.40-27.47); the median charge of PK studies during cycle 1 was $43.24 (36.93-80). The number of PK time points and the amount of PK charges did not significantly correlate with monotherapy vs. combination regimens, oral vs. parenteral route, or small molecules vs. other (cytotoxic, vaccine, monoclonal antibodies). However, protocols (all cycles combined) with small molecules had a trend of lower PK time point median charges (41.97 vs. 52.67; p=0.09). Analysis of PKs in cycle 1 demonstrated that protocols with small molecules had a trend of higher PK time point median charges (61.33 vs. 42.38; p=0.08). Conclusions: The number and charges of PK studies was independent of the study drug or route. Future studies comparing budgeted vs. performed PKs and industry vs. investigator-initiated trials are warranted.
Abstract OT1-01-02: A phase II trial of neoadjuvant docetaxel/cyclophosphamide followed by epirubicin/cyclophosphamide for triple-negative breast cancer
Authors: N Tanaka, A Hirano, H Inoue, K Ogura, A Hattori, N Jibiki, H Yukawa, A Matsuoka, A Kodera, M Kamimura, Y Naritaka, T Shimizu
Journal: Cancer Research (2017)

Abstract Background Currently, an anthracycline followed by a taxane as adjuvant or neoadjuvant chemotherapy is considered the most effective treatment for patients with triple-negative breast cancer. However, docetaxel followed by an anthracycline as neoadjuvant chemotherapy results in a higher rate of pathological complete response (pCR) than the regimen including an anthracycline followed by docetaxel (Iwata et al. Jpn J Clin Oncol 2011). Adjuvant docetaxel/cyclophosphamide (DC) treatment resulted in prolonged survival compared to adjuvant doxorubicin/cyclophosphamide. Therefore, we planned a phase II trial of DC followed by epirubicin/cyclophosphamide (EC) (Trial registration: UMIN000011031). Trial design This is a phase II trial to evaluate the efficacy and toxicity of DC followed by EC as neoadjuvant therapy for triple-negative breast cancer. Patients will receive four cycles of docetaxel (75 mg/m2) and cyclophosphamide (600 mg/m2) every 21 days, followed by four cycles of epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) every 21 days. Eligibility criteria Patients with histologically diagnosed triple-negative breast cancer, T1–4, N1–3, or T2–T4, N0 based on a core needle biopsy, will be included in this trial. Eligible patients must be between 20 and 70 years of age with a performance status of 0–2 and adequate organ function. They must not have undergone any prior operation, radiation therapy, chemotherapy, endocrine therapy, or immunotherapy. Specific aims The primary endpoint is the pCR rate in the breast and axilla, and the secondary endpoints are the breast-conserving rate, toxicities, feasibility, and 5-year overall survival and relapse-free survival. pCR is defined as disappearance of invasive cancer cells, including those in the axilla, although the presence of residual intraductal cancer is acceptable. Statistical methods The sample size was calculated using the Simon method, with a type I error of 10% and a study power of 80%. The expected pCR rate is 25%, with a threshold pCR rate of 10%, and the required number of patients has been estimated to be 33. Present and target accrual Patient accrual within two medical centers was started in September 2013. We plan to enroll a total of 34 patients in the trial. Citation Format: Tanaka N, Hirano A, Inoue H, Ogura K, Hattori A, Jibiki N, Yukawa H, Matsuoka A, Kodera A, Kamimura M, Naritaka Y, Shimizu T. A phase II trial of neoadjuvant docetaxel/cyclophosphamide followed by epirubicin/cyclophosphamide for triple-negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT1-01-02.
Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)
Authors: Barbara F. Eichhorst, Jasmin Bahlo, Christian Maurer, Elisabeth Lange, Hubert Köppler, Michael G Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling-Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Marco Herling, Kirsten Fischer, Hartmut Döhner, Michael Kneba, Clemens Wendtner, Wolfram Klapper, Karl-Anton Kreuzer, Sebastian Böttcher, Stephan Stilgenbauer, Anna Maria Fink, Michael Hallek
Journal: Blood (2016)
Abstract P2-07-03: Insulin and breast cancer risk: Novel insights from mammographic density analyses
Authors: S Borgquist, AH Rosendahl, K Czene, N Bhoo-Pathy, M Dorkhan, P Hall, JS Brand
Journal: Cancer Research (2017)

Abstract Background: Insulin has been suspected to influence breast cancer risk because of its mitogenic effects and impact on sex hormone levels. Epidemiological studies investigating breast cancer occurrence in insulin-treated patients with diabetes have produced conflicting results, but were often underpowered and lacked adequate control for important confounders. Purpose: To investigate the impact of insulin treatment on mammographic density (MD) as intermediate phenotype for breast cancer risk, and to further explore causation by analyzing associations with a polygenic risk score (PRS) incorporating 18 single nucleotide polymorphisms (SNPs) associated with fasting insulin levels. Design: We conducted a matched cohort study within a Swedish screening-based cohort including insulin-treated type 1 (T1D, N=122) and type 2 (T2D, N=237) diabetes patients and up to 5 non-diabetic women matched on birth year (N=1,780). Associations between diabetes status and duration of insulin use with volumetric mammographic density were analyzed using general linear models adjusting for a comprehensive set of potential confounders. PRS analyses were performed in an independent sample of non-diabetic women (N=9,437) from the same cohort. Results: In multivariable analyses, T1D patients had higher percent (11.2 vs. 8.8%; P&amp;lt;0.001) and absolute dense volumes (66.6 vs. 60.8 cm3; P=0.09) and a lower absolute non-dense volume (513.2 vs. 617.7 cm3; P&amp;lt;0.001) compared to age-matched non-diabetics. Percent- and absolute dense volumes increased with increasing T1D duration, while no such trend was observed for the absolute non-dense volume. Similar associations but of smaller magnitude, were found in insulin-treated T2D patients. Genetically predicted higher fasting insulin levels among non-diabetes women were associated with increased percent and absolute dense volumes (% change per sd increase in PRS = 0.8 (0.0-1.6) and 0.9 (0.1-1.8) respectively), but no difference in absolute non-dense volume. Conclusions: Our results demonstrate higher mammographic density among insulin-treated diabetes patients, and genetic analyses support an effect of insulin on volumetric mammographic density. Further studies into how the observed MD differences translate into breast cancer risk are warranted. Citation Format: Borgquist S, Rosendahl AH, Czene K, Bhoo-Pathy N, Dorkhan M, Hall P, Brand JS. Insulin and breast cancer risk: Novel insights from mammographic density analyses [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-07-03.
NR2F6 (EAR-2) Is a Novel Leukemia Oncogene Whose Cellular Function Is to Regulate Terminal Differentiation of Erythrocytes at the Proerythroblast Stage
Authors: Christine Victoria Ichim, Dzana Dervovic, David Koos, Marciano D. Reis, Alden Chesney, Richard A. Wells
Journal: Blood (2014)
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
Authors: Cynthia X. Ma, Feng Gao, Jingqin Luo, Donald W. Northfelt, Matthew Goetz, Andres Forero, Jeremy Hoog, Michael Naughton, Foluso Ademuyiwa, Rama Suresh, Karen S. Anderson, Julie Margenthaler, Rebecca Aft, Timothy Hobday, Timothy Moynihan, William Gillanders, Amy Cyr, Timothy J. Eberlein, Tina Hieken, Helen Krontiras, Zhanfang Guo, Michelle V. Lee, Nicholas C. Spies, Zachary L. Skidmore, Obi L. Griffith, Malachi Griffith, Shana Thomas, Caroline Bumb, Kiran Vij, Cynthia Huang Bartlett, Maria Koehler, Hussam Al-Kateb, Souzan Sanati, Matthew J. Ellis
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) assessed the antiproliferative activity of the CDK4/6 inhibitor palbociclib in primary breast cancer as a prelude to adjuvant studies. Experimental Design: Eligible patients with clinical stage II/III ER+/HER2− breast cancer received anastrozole 1 mg daily for 4 weeks (cycle 0; with goserelin if premenopausal), followed by adding palbociclib (125 mg daily on days 1–21) on cycle 1 day 1 (C1D1) for four 28-day cycles unless C1D15 Ki67 &amp;gt; 10%, in which case patients went off study due to inadequate response. Anastrozole was continued until surgery, which occurred 3 to 5 weeks after palbociclib exposure. Later patients received additional 10 to 12 days of palbociclib (Cycle 5) immediately before surgery. Serial biopsies at baseline, C1D1, C1D15, and surgery were analyzed for Ki67, gene expression, and mutation profiles. The primary endpoint was complete cell cycle arrest (CCCA: central Ki67 ≤ 2.7%). Results: Fifty patients enrolled. The CCCA rate was significantly higher after adding palbociclib to anastrozole (C1D15 87% vs. C1D1 26%, P &amp;lt; 0.001). Palbociclib enhanced cell-cycle control over anastrozole monotherapy regardless of luminal subtype (A vs. B) and PIK3CA status with activity observed across a broad range of clinicopathologic and mutation profiles. Ki67 recovery at surgery following palbociclib washout was suppressed by cycle 5 palbociclib. Resistance was associated with nonluminal subtypes and persistent E2F-target gene expression. Conclusions: Palbociclib is an active antiproliferative agent for early-stage breast cancer resistant to anastrozole; however, prolonged administration may be necessary to maintain its effect. Clin Cancer Res; 23(15); 4055–65. ©2017 AACR.
Six Cycles of ABVD and a Negative PET Scan Negates the Need for Radiologic Follow-up in Early Stage, Non-Bulky Hodgkin Lymphoma: MSKCC Retrospective Analysis
Authors: Sidonie K Hartridge-Lambert, Heiko Schoder, Remy C Lim, Jocelyn C Maragulia, Carol S Portlock
Journal: Blood (2011)
Expression of the Wilms’ Tumor 1 (WT1) Gene Renders Acute Promyelocytic Leukemia Cells Resistant to All-Trans-Retinoic-Acid-Induced Differentiation.
Authors: Aschwin L. Menke, Ruth H.J.N. Knops, Jurgen A.F. Marteijn, Willemijn Wissink, Josie Smeets, Arnold van Piekeren, Gerty Vierwinden, Theo de Witte, Bert A. van der Reijden, Joop H. Jansen
Journal: Blood (2005)
Whole Genome Sequencing in Sequential Biopsies Reveals the Genetic Evolution of Follicular Lymphoma to Transformed Follicular Lymphoma
Authors: Jessica Okosun, Csaba Bödör, Jun Wang, Shamzah Araf, Jacek Marzec, Sameena Iqbal, Janet Matthews, Maria Calaminici, Ciaran O'Riain, Derville O'Shea, Emanuela Carlotti, Andrew Davies, David Wrench, András Matolcsy, T. Andrew Lister, John G Gribben, Silvia Montoto, Claude Chelala, Jude Fitzgibbon
Journal: Blood (2012)
Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Non-Compliance, Diet, Smoking, Co-Medications (including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function
Authors: Andrew L. Frelinger, Deepak L. Bhatt, Ronald D. Lee, Darcy J. Mulford, Jingtao Wu, Sai Nudurupati, Anu Nigam, Michael Lampa, Julie K. Brooks, Marc R. Barnard, Alan D. Michelson
Journal: Blood (2012)
Proteomic Analysis of Chronic Malignant B-Cell Derived Microparticles Reveals CD148 as a Potential Antigenic Marker for Mantle Cell Lymphoma Diagnosis.
Authors: Laurent Miguet, Luc-Matthieu Fornecker, Claire Felden, Carine Gervais, Raoul Herbrecht, Sarah Sanglier, Alain van Dorsselaer, Laurent Mauvieux
Journal: Blood (2008)
Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
Authors: Kwang Il Seo, Byung Chul Yun, Weiquan James Li, Sang Uk Lee, Byung Hoon Han, Eun Taek Park
Journal: Clinical and Molecular Hepatology (2017)

Interferon-based treatment is not appropriate for a large number of patients with chronic hepatitis C for various medical and social reasons. Newly developed directly acting antivirals (DAAs) have been used to treat chronic hepatitis C without severe adverse effects and have achieved a sustained viral response (SVR) rate of 80-90% with short treatment duration. We were interested to determine whether all patients who failed to respond to or were ineligible for interferon-based therapy could be treated with DAAs.Medical records of patients with positive serum anti-hepatitis C virus (HCV) or HCV RNA between January 2009 and December 2013 were reviewed. Demographic, clinical, and treatment data were collected for analysis.A total of 876 patients were positive for both anti-HCV and HCV RNA. Of these, 244 patients were eligible for interferon, although this was associated with relapse in 39 (16%) of patients. In total, 130 patients stopped interferon therapy (67% adverse effects, 28% non-adherent, 4% malignancy, 1% alcohol abuse) and 502 patients were ineligible (66% medical contraindications, 25% non-adherent, 5% socioeconomic problems). Among 671 patients who were ineligible for or failed to respond to interferon therapy, more than 186 (27.7%) could not be treated with DAA due to financial, social, or cancer-related conditions.Newly developed DAAs are a promising treatment for patients with chronic hepatitis C who are ineligible for or failed to respond to interferon-based therapy. Nevertheless, not all chronic hepatitis C patients can be treated with DAAs due to various reasons.
US Uterus Transplant Trials Under Way
Authors: Bridget M. Kuehn
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Alloimmunization Does Not Modify the Clinical Profile of Sickle Cell Disease Patients from Salvador-Brazil
Authors: Angela Zanette, Karla O. Mota, Marilda Souza Goncalves, Laise Vilasboas Schettini, Lais Magalhaes Aguiar, Claudio Jose Freitas Brandão, Ana Cláudia Neves Azevedo, Luciana Nogueira, Sérgio Arruda
Journal: Blood (2008)
Attributing Death to Diet
Authors: Noel T. Mueller, Lawrence J. Appel
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P6-07-34: The prognostic impact of inositol polyphosphate 5-phosphatase PIPP (INPP5J) expression in breast cancer tissue
Authors: N Kondo, T-S Kim, Y Wanifuchi, Y Hato, T Hisada, M Nishimoto, S Nishikawa, T Toyama
Journal: Cancer Research (2017)

Abstract Background : Inositol polyphosphate 5-phosphatase PIPP (INPP5J) has been identified as a suppressor of oncogenic PI3K/Akt signaling in breast cancer.INPP5J depletion increases transformation and accelerates oncogene-driven tumor growth in vivo, while paradoxically reducing cell migration, invasion, and metastasis. Therefore, we hypothesized that INPP5J gene expression in human breast cancer tissues would be prognostic in early breast cancer patients over long-term follow-up. Methods: A total of 478 breast cancer tissue samples collected between 2003 and 2008 was available for analysis. We measured INNPP5J mRNA using a TaqMan gene expression assay. PIK3CA mutation status was evaluated using a TaqMan mutation detection assay. We then investigated the correlations of clinicopathological factors and prognosis with levels of INPP5J mRNA and the PIK3CA mutation status. Results: INPP5J mRNA was expressed at a low level in 30.1% (144/478) and at a medium to high level in the remaining breast cancer samples. Low INPP5J mRNA correlated with larger tumor (p=0.015), high grade (p&amp;lt;0.0001) and, ER-negativity (p&amp;lt;0.0001). PIK3CA mutations were detected in 46% (63/138) of patients analyzed. We found that disease-free survival (DFS) was significantly worse in patients with low levels of INPP5J (p=0.008). Although DFS and INPP5J levels tended to be associated in estrogen receptor (ER)-positive patients (p=0.052), DFS was significantly worse in patients with wild-type PIK3CA and low INPP5J mRNA expression (p=0.008). Conclusion: We shows that the level of INPP5J mRNA expression is prognostics in breast cancer patients and that its prognostic impact is affected by PIK3CA mutation status. Citation Format: Kondo N, Kim T-S, Wanifuchi Y, Hato Y, Hisada T, Nishimoto M, Nishikawa S, Toyama T. The prognostic impact of inositol polyphosphate 5-phosphatase PIPP (INPP5J) expression in breast cancer tissue [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-07-34.
No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience
Authors: Eirini Katodritou, Evangelos Terpos, Sosana Delimpasi, Argiris Symeonidis, Panagiotis Repousis, Marie-Christine Kyrtsonis, Eurydiki Michalis, Maria Papathanasiou, Genovefa Polychronidou, Christina Hadjiaggelidou, Alexandra Kouraklis, Ioannis Patsias, Maria Gavriatopoulou, Efstathios Kastritis, Maria Kotsopoulou, Evgenia Verrou, Vassiliki Gastari, Evlambia Giannopoulou, Nikos Spyridis, Pavlina Konstantinidou, Anastasia Pouli, Achilles Anagnostopoulos, Meletios A. Dimopoulos
Journal: Blood (2014)